The potency of DNA vaccines may be affected by the efficiency of intracellular processing and MHC class I presentation of encoded antigens. Since a single-chain trimer (SCT) composed of peptide, b2-microglobulin (b2m), and MHC class I heavy chain has been shown to bypass antigen processing and lead to stable presentation of peptides, we investigated the efficacy of a DNA vaccine encoding a SCT composed of an immunodominant CTL epitope of human papillomavirus type 16 (HPV-16) E6 antigen, b2m, and H-2K b MHC class I heavy chain (pIRES-E6-b2m-K b ). Transfection of 293 cells with pIRES-E6-b2m-K b can bypass antigen processing and lead to stable presentation of E6 peptide. Furthermore, C57BL/6 mice vaccinated with pIRES-E6-b2m-K b exhibited significantly increased E6 peptide-specific CD8 + T-cell immune responses compared to mice vaccinated with DNA encoding wild-type E6. Most importantly, 100% of mice vaccinated with pIRES-E6-b2m-K b DNA were protected against a lethal challenge of E6-expressing TC-1 tumor cells. In contrast, all mice vaccinated with wild-type E6 DNA or control plasmid DNA grew tumors. Our data indicate that a DNA vaccine encoding a SCT can lead to stable enhanced MHC class I presentation of encoded antigenic peptide and may be useful for improving DNA vaccine potency to control tumors or infectious diseases.
Introduction
DNA vaccines have become potentially important immunotherapeutic agents for combating cancers (for a review see Boyd et al 1 ). Compared to live viral or bacterial vectors, naked plasmid DNA vaccines are safe and can be administered repeatedly. Other benefits of DNA vaccines include easy preparation on a large scale with high purity and high stability relative to proteins and other biological agents. 2, 3 One concern involved with naked DNA vaccines is their limited potency, as naked DNA does not have the inherent ability to replicate in vivo. Therefore, attempts have been made to improve the potency of DNA vaccines by targeting DNA to professional antigen-presenting cells (APCs) and by modifying the properties of DNA-transfected APCs (for reviews see Boyd et al 1 and Hung and Wu 4 ). One important strategy for improving DNA vaccine potency is enhancement of MHC class I presentation of encoded antigen by APCs. The potency of DNA vaccines depends on the efficient expression and presentation of the encoded antigen of interest, which is processed in the cytoplasm and presented by MHC class I molecules on the surface of APCs, leading to a cellular and/or humoral immune response against the antigen in immunized individuals. MHC class I antigen processing involves cutting of protein antigen into peptide fragments by a proteasome, transport by TAP into the endoplasmic reticulum lumen, loading onto newly assembled MHC class I heavy chain and b2 microglobulin (b2m), and delivery of the MHC:peptide complex to the cell surface. Each of these steps is under extensive regulation and affects the robustness of immune response generated (for a review, see Pamer and Cresswell 5 ). We attempted to circumvent antigen processing and elicit stable MHC class I presentation of the antigenic peptide encoded by our DNA vaccine by employing a single-chain construct encoding MHC class I linked to peptide. [6] [7] [8] By linking together the antigen peptide, b2m, and MHC class I heavy chain into a single-chain trimer (SCT), as illustrated in Figure 1a , it has been shown that stable cell surface expression of the chimeric protein can be detected in DNA-transfected cells using antibodies specific to the antigenic peptide within the trimer. This indicates that the peptide in such SCT must be in an orientation similar to noncovalently attached peptides. 8 A major advantage of this approach is that normal antigen processing, which might be regulated by cellular machinery, leading to uncertainties in immunogenicity, may be bypassed. Furthermore, stability is conferred to the MHC:peptide complex by the covalent bonding between the three molecules of the trimer. Also, the antigenic peptide can be selected so that the most immunogenic epitope may be used, which is not possible in conventional antigen-coding DNA vaccines, where proteasome degradation and peptide loading onto MHC class I molecules determines the nature of presented epitopes.
A DNA vaccine encoding SCT of MHC class I linked to the immunodominant CTL epitope of a tumor antigen has not been tested for the ability to protect against antigen-expressing tumors. For this study, we constructed a DNA vaccine encoding an SCT containing aa49-57 of the human papillomavirus-16 (HPV-16) E6 protein (pIRES-E6-b2m-K b ) and tested its ability to induce protective immunity against the HPV-transformed TC-1 murine tumor model. 9 HPV infection, particularly high-risk HPV type-16, is causally linked to the development of cervical cancer and has been linked to other cancers (for a review, see zur Hausen 10 ). HPV oncoprotein E6 is responsible for malignant transformation of HPV-infected cells and is consistently expressed in HPV-associated tumor cells. The E6 protein therefore represents an ideal target antigen for HPV vaccine development. E6 aa48-57 was recently identified as a peptide sequence containing an H2-K b -restricted immunodominant CTL epitope of the E6 protein in C57BL/6 mice, 11 and further studies have indicated that E6 aa50-57 and E6 aa49-57 also function as CTL epitopes of E6 in C57BL/6 mice. We found that vaccination of mice with pIRES-E6-b2m-K b resulted in stronger E6-specific cellular immune responses and antitumor effects than vaccination of mice with DNA encoding full-length E6 protein. Our findings thus suggest that a DNA vaccine encoding a SCT specific for an HPV antigen has potential clinical application for the control of HPV infection and HPV-related cancers. 
Results

T-cell responses in vaccinated mice
To assess the immunogenicity of our E6-b2m-K b SCT, we vaccinated mice with pIRES-E6-b2m-K b , pIRES-E6, or pIRES-OVA-b2m-K b , and then performed intracellular cytokine staining with flow cytometry analysis to characterize E6-specific CD8 + T-cell precursors using E6 aa49-57 peptide as a stimulant. As shown in Figure 3 To determine the subsets of lymphocytes that are important for the protection against E6-expressing tumor cells, we performed in vivo antibody depletion experiments. As shown in Figure 5b , all of the mice depleted of CD8 + T cells grew tumors within 1 week of tumor challenge. In contrast, all of the nondepleted, NK-or CD4 + T-cell-depleted mice remained tumor-free 6 weeks after tumor challenge. These results indicate that CD8 + T cells are essential for the protective antitumor immunity generated by the pIRES-E6-b2m-K b DNA vaccine.
Treatment with pIRES-E6-b2m-K b DNA eradicates established E6-expressing tumors in the lungs
The therapeutic potential of each vaccine was assessed by performing an in vivo tumor treatment experiment using a previously described lung hematogeneous spread model. 12 Mice were challenged with TC-1 tumor cells via tail vein injection followed by treatment with DNA. As shown in Figure 6 , C57BL/6 mice treated with pIRES-E6-b2m-K b DNA exhibited the lowest mean number of pulmonary tumor nodules (1472), significantly lower than mice treated with pIRES-E6 DNA (6576) or pIRES-OVA-b2m-K b DNA (6776) (one-way analysis of variance (ANOVA), Po0.01). These data indicated that treatment with pIRES-E6-b2m-K b DNA -transfected 293 cells also suggests high-level surface expression of the SCT. This is a particularly useful strategy for antigens, such as HPV-16 E6 protein, whose immunodominant epitopes are not efficiently processed and presented by the MHC class I pathway 11 (also see Figures 2 and 3 ). Our data are consistent with a previous study by Yu et al, 8 showing that the covalently bound peptide of an SCT resides stably in the peptide binding groove of the MHC class I molecule, excluding loading of other peptides.
Direct delivery of DNA encoding SCT to professional APCs is probably important for SCT-encoding DNA vaccines to work efficiently. Intradermal administration of DNA vaccines via gene gun has been shown to deliver efficiently DNA into professional APCs (Langerhans cells). 13 In comparison, intramuscular injection of DNA vaccines likely delivers DNA to muscle cells. Since muscle cells do not have sufficient costimulatory molecules for the activation of antigen-specific T cells, such as B7.1 and B7.2, presentation of the SCT by muscle cells will not likely result in a significant activation of antigen-specific, CD8 + T cells. A DNA vaccine encoding SCT could also be used in combination with other strategies to further enhance immunogenicity of DNA vaccines. The SCT strategy enhances immunogenicity of DNA vaccines by bypassing antigen-processing pathways to improve MHC class I presentation of encoded antigenic peptide on the surface of professional APCs such as dendritic cells (DC). We have previously coadministered DNA encoding antiapoptotic proteins with DNA encoding antigen to prolong the life of DCs in vivo.
14,15 As these two strategies modify the properties of DCs through different pathways, it should be feasible to coadminister DNA encoding antiapoptotic proteins with DNA encoding SCT to further enhance antigen-specific immune responses to vaccination. Different approaches to link MHC class I heavy chain and b2m to peptide to make a functional single-chain molecule capable of stimulating antigen-specific T cells have been reported, 6, 8, [16] [17] [18] [19] [20] although some are applicable only to certain MHC class I:peptide complexes. An SCT construct in the format used in this study, the 'peptidespacer-b2m-spacer-heavy chain' format, has been reported to be applicable to a wider range of MHC class I:peptide complexes. 8, 19, 21 For this reason, we chose this format for the construction of our E6-b2m-K b SCT, and our data are consistent with these prior reports.
In this study, we have shown that vaccination with an E6 DNA vaccine encoding SCT can generate a better therapeutic antitumor effect compared to a DNA vaccine encoding wild-type E6 (Figure 6 ). While the tumor dose we used for our in vivo tumor treatment experiment (10 4 TC-1 tumor cells) may not form a grossly visible lung tumor 3 days after tumor challenge, this tumor dose has been shown to generate multiple grossly visible lung tumors in 4 weeks and eventually kill the challenged mice if the mice were left untreated. 12 We used this experimental design to demonstrate the ability of our DNA vaccine to control 'minimal residual disease'. Minimal residual disease (such as tumor spread through metastasis) is a major concern for cancer patient management after patients receive initial treatment such as surgery or radiotherapy. The lung hematogeneous spread tumor model represents a model of minimal residual disease in the challenged mice. Our data suggest that an E6 DNA vaccine employing an SCT may potentially generate therapeutic effects against minimal residual disease of HPV-associated malignancies.
One limitation of an MHC class I SCT vaccination strategy is its restriction to presentation of a single antigenic epitope. It is known that expression of tumorassociated antigens or epitopes of antigens can vary between tumors in different hosts or between tumors within a single host. Therefore, therapeutic tumor vaccines targeting multiple tumor-associated antigens or multiple epitopes of a single antigen would likely be more effective than therapeutic vaccines targeting a single epitope. Although a DNA vaccine encoding a SCT is restricted to targeting a single antigenic epitope, multiple SCT-encoding DNA vaccines could be coadministered to elicit an immune response specific for multiple epitopes of the same or different tumorassociated antigens. Thus, DNA vaccines encoding SCT could potentially be used to elicit immune responses against multiple antigens for immunotherapy of cancers with well-defined tumor-specific antigens such as cervical cancer or melanoma.
With the continuing identification of new cancerrelated antigens and their epitopes, this SCT strategy may serve as a general technique for the development of effective DNA vaccines against neoplasia. Since SCT can be directly expressed on the cell surface without processing, this allows control over which peptide is presented by a specific MHC class I molecule. Thus, the most immunodominant epitope can always be chosen, as we did in this study. It may also be possible to further enhance antitumor immunity by introducing mutations into the peptide or MHC class I molecule of an SCT. For Figure 6 In vivo tumor treatment experiments to demonstrate the therapeutic effect of pIRES-E6-b2m-K b in controlling pulmonary tumor cell growth. Mice (five per group) were challenged with 1 Â 10 4 tumor cells 3 days prior to DNA vaccination. The mean number of lung tumor nodules generated in each vaccinated group was determined on day 30 after tumor challenge.
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C-H Huang et al example, mutation of heavy chain intended to better accommodate the linker between the peptide and MHC molecule was shown to enhance immune presentation, 19 and altered peptide (such as heteroclitic peptide), which stabilizes MHC-peptide-TCR complexes strengthens antitumor immunity. 22 Most recently, SCT technology has been extended to human MHC class I molecules. SCT composed of either an HLA-A2 or an HLA-B27 molecule linked to peptide can be detected by peptide-specific CTL and antibodies (Hansen et al, personal communication).
In conclusion, our results demonstrate that a DNA vaccine encoding an SCT consisting of MHC class I linked to a CTL epitope of a tumor antigen effectively induces protective antitumor immunity through direct presentation of the CTL epitope on the cell surface by the linked MHC class I molecule. This strategy may serve as a convenient means for development of DNA vaccines to control other tumors and infectious diseases.
Materials and methods
Plasmid DNA constructs and DNA preparation
The plasmid encoding SCT OVA-b2m-K b (pIRES-OVAb2m-K b ) has been described previously. 8 For the generation of E6 aa49-57-b2m-K b -expressing plasmid, an insert containing the immunodominant E6 aa49-57 epitope 11 and flanking AgeI/NheI restriction enzyme sites was made by annealing two single-stranded oligo-nucleotides (5 0 -CCGGTTTGTATGCTGTATATGACTTTGCTTTT CGGGATTTAGGAGGAGGTG-3 0 and 5 0 -CTAGCACCT CCTCCTAAATCCCGAAAAGCAAAGTCATATAAGCA TACAAA-3 0 ). It was then cloned into pIRES-OVA-K b using AgeI/NheI sites to replace the OVA epitope, generating pIRES-E6-b2m-K b . Full-length E6 protein, previously cloned in pcDNA plasmid vector (pcDNA-E6), 11 was subcloned into pIRES using NotI/BamHI sites to generate pIRES-E6. Figure 1b shows the different constructs used in this study. For the generation of pcDNA3-K b DNA, DNA encoding K b was first amplified by RT-PCR with a Superscript One-Step RT-PCR system (Invitrogen, Carlsbad, CA, USA) using cDNA derived from the TC-1 cell line as a template and a set of primers, 5 0 -AAAGAATTCATGGTACCGTGCA CGCTGCTC-3 0 and 5 0 -TTTGGATCCTCACGCTAGAGA ATGAGGGTC-3 0 . The amplified product was then cloned into the EcoRI/BamHI cloning sites of the pcDNA3 vector. All plasmid constructs were confirmed by DNA sequencing. The DNA was amplified in Escherichia coli DH5a and purified as described previously. 23 DNA for vaccination was prepared using an endotoxin-free kit (Qiagen, Valenci, CA, USA).
Cells
The HPV-16 E6-expressing murine tumor model, TC-1, has been described previously. Briefly, the T-cell line was stimulated with an irradiated HPV-16 E6-expressing tumor cell line, TC-1, in the presence of IL-2 (20 U/ml) once a week. The specificity of the CTL lines was characterized by staining for CD8 and by determining the ability of the T cells to kill E6 peptide-pulsed EL-4 cells.
In vitro transfection
The 293 or 293-K b cells were seeded in six-well plate at a density of 5 Â 10 5 cells/well the day before transfection. Plasmid (5 mg) was used to transfect each well using Lipofectamine 2000 (Invitrogen). The transfected cells were used 24 h later.
Transfected or untransfected 293 or 293-K b cells were washed with complete RPMI-1640 containing 10% fetal bovine serum, and coincubated with HPV-16 E6 aa49-57 peptide-specific T cells (with a ratio 1:2.5) at the presence of 1 ml/ml of GolgiPlug (BD Pharmingen) at 371C overnight. Intracellular staining of IFN-g, flow cytometry and data analysis were performed as described below.
Mice
Female C57BL/6 mice (6-8 weeks old) were purchased from the National Cancer Institute (Frederick, MD, USA) and kept in the oncology animal facility of the Johns Hopkins Hospital (Baltimore, MD, USA). All animal procedures were performed according to approved protocols and in accordance with recommendations for the proper use and care of laboratory animals.
DNA vaccination
DNA-coated gold particles were prepared according to a previously described protocol. 23 DNA-coated gold particles were delivered to the shaved abdominal region of mice using a helium-driven gene gun (BioRad, Hercules, CA, USA) with a discharge pressure of 400 p.s.i. C57BL/ 6 mice were immunized with 2 mg of pIRES-E6-b2m-K b , pIRES-E6, or pIRES-OVA-b2m-K b . The mice received three boost vaccinations with the same dose at 1-week intervals.
Intracellular cytokine staining and flow cytometry analysis
Splenocytes were harvested from mice (five per group) 1 week after the last vaccination. Cell surface CD8 marker staining, intracellular IFN-g staining and flow cytometry analysis were performed as described previously. 23 Briefly, 4 Â 10 6 pooled splenocytes from each vaccination group were incubated with 1 mg/ml of E6 aa49-57 peptide in the presence of 1 ml/ml of GolgiPlug (BD Pharmingen) at 371C overnight. Cells were then washed with FACScan buffer and stained with phycoerythrinconjugated monoclonal rat anti-mouse CD8 antibody, followed by intracellular cytokine staining with FITCconjugated IFN-g using the Cytofix/Cytoperm kit according to the manufacturer's instructions (BD Pharmingen, San Diego, CA, USA). Analysis was performed on a Becton-Dickinson FACScan with CELLQuest software (Becton Dickinson Immunocytometry System, Mountain View, CA, USA).
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In vivo tumor protection experiment
For the tumor protection experiment, C57BL/6 mice (five per group) were immunized via gene gun with 2 mg of pIRES-E6-b2m-K b , pIRES-E6, or pIRES-OVA-b2m-K b . Three boosters using the same regimen were given at 1-week intervals. At 1 week after the last vaccination, each mouse was challenged with 5 Â 10 4 TC-1 tumor cells subcutaneously in the right leg and then monitored twice a week.
In vivo tumor treatment experiment
For the tumor treatment experiments, mice (five per group) were challenged with 1 Â 10 4 TC-1 tumor cells/ mouse in the tail vein to simulate hematogenous spread of tumors. DNA vaccines were given 3 days after tumor challenge at a dose of 2 mg/mouse, followed by two boosters of the same dose at 1-week intervals. Mice were killed on day 30 after tumor challenge.
In vivo antibody depletion experiment
To study the subsets of lymphocytes that are important for the antitumor effects, a tumor protection experiment was performed as described above, coupled with in vivo antibody depletion of CD4 T cells, CD8 T cells, and NK cells, using the method described previously. 9 Briefly, mAb GK1.5, mAb 2.43, and mAb PK136 (Harlan, Indianapolis, IA, USA) were used for CD4 depletion, CD8 depletion, and NK1.1 depletion, respectively. We have confirmed that more than 95% depletion of the CD8 or CD4 T cells and more than 90% of NK cells were achieved with normal levels of the other subsets. Mice (five per group) were monitored twice a week and killed on day 42 after tumor challenge.
Statistical analysis
All data expressed as means7s.e.m. are representative of at least two different experiments. Data for intracellular cytokine staining with flow cytometry analysis were evaluated by ANOVA. Comparisons between individual data points were made using a Student's t-test. For statistical analysis of the tumor protection and antibody depletion experiments, we used Kaplan-Meier analysis.
